Summary
BeiGene, Ltd. has announced its intention to change its corporate name to "BeOne Medicines Ltd.", a move that will also coincide with a ticker symbol change to "ONC" on The Nasdaq Global Select Market. This rebranding signifies the company's reinforced commitment to developing innovative medicines aimed at eliminating cancer, emphasizing a collaborative, global approach to patient care. The proposed name change is subject to shareholder approval, which will be sought at a future shareholder meeting. Investors should pay close attention to the upcoming definitive proxy statement, which will provide comprehensive details regarding the name change proposal and related matters. This document will be available for free on the SEC's website and directly from the company. The company also notes that its directors and executive officers may be considered participants in the solicitation of proxies for this vote, and further information on their interests will be disclosed in the proxy statement.
Key Highlights
- 1BeiGene, Ltd. intends to change its corporate name to "BeOne Medicines Ltd."
- 2The company's ticker symbol on The Nasdaq Global Select Market is expected to change to "ONC".
- 3The name change reflects a commitment to developing innovative medicines to eliminate cancer through global partnerships.
- 4The proposed name change requires shareholder approval at a future meeting.
- 5A definitive proxy statement detailing the name change proposal will be filed with the SEC and provided to shareholders.
- 6Shareholders are urged to read the definitive proxy statement for important information.
- 7The company will provide free access to the proxy statement and other relevant SEC filings.